Caris Life Sciences
Whole-exome and whole-transcriptome tumour profiling at scale, with a large real-world database.
MI Profile (WES + WTS), Caris Assure (blood), MI Cancer Seek (FDA-approved 2024); IPO 2025.
Pages like this
not linked directly; found by shared links- CompanyValius Sciences
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- PersonStefan Fröhling
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- TermNext-generation sequencing (NGS)
Shares Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- IdeaLink every national cancer registry to tumour genomics
Shares Every tumour genomic report machine-readable and deposited nationally, Whole-exome & whole-genome sequencing.
- CollectionCIViC
Shares Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally.
- IdeaA standard evolvability score for every tumour
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- CollectionOncoKB
Shares Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Comprehensive genomic profiling.
- InstitutionOntario Institute for Cancer Research
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.